Similarly, loss of function mutations in the negative PI3K regulators, NF1 and PTEN or activating NRAS mutations, did not significantly reduce the sensitivity of BRAFV600E-mutant melanoma cells to trametinib (Fig. 1a). This evidence concerns the gene NRAS and melanoma.